Trial intelligence / Profile preview

Adapalene Gel 0.1% vs Differin in Acne Vulgaris

NCT04797793Phase 1Completed

Start
May 2020
Primary completion
Jan 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, double-blind trial of adapalene in acne vulgaris (3 arms). Primary endpoint: The percentage change in the inflammatory and non-inflammatory lesion counts at 12 weeks. Started May 2020; status: completed.

02

Drugs

adapalene
03

Conditions

acne vulgaris

Beyond the preview

Go deeper on NCT04797793.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04797793.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call